Clinical Trials Browser

Phase 2 × niraparib × Gynecologic × Clear all

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Phase 2 Active not recruiting

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT04068753 2026-02-10

STAR

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT06180356 2025-11-28

ANALLISA

Phase 2 Recruiting

Ovarian Neoplasms

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Phase 2 Terminated

36 enrolled 11 charts

Ovarian Neoplasms

NCT05169437 2025-10-29

PAVO

Phase 2 Terminated

22 enrolled 17 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT04641247 2025-09-29

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

Phase 2 Recruiting

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT04080284 2025-08-19

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

Phase 2 Completed

Uterine Neoplasms, Endometrial Neoplasms

NCT03326193 2025-07-31

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 2 Completed

105 enrolled 29 charts

Ovarian Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT05335993 2025-07-10

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03783949 2025-06-11

EUDARIO

Phase 2 Completed

122 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05990192 2025-04-22

SOPRANO

Phase 2 Recruiting

Ovarian Neoplasms

NCT05523440 2025-03-28

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Phase 2 Terminated

Ovarian Neoplasms, Endometrial Neoplasms

NCT03891576 2025-01-17

Newton

Phase 2 Terminated

Classical hematologyGynecologic

Anemia, Fallopian Tube Neoplasms, Neutropenia, Ovarian Neoplasms, Recurrence, Thrombocytopenia

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT05183984 2024-10-16

NIRVANA-1

Phase 2 Recruiting

Ovarian Neoplasms

NCT03759600 2024-07-16

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Phase 2 Completed

20 enrolled 42 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03759587 2024-06-07

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Phase 2 Completed

19 enrolled 39 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Phase 2 Unknown

Endometrial Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05961124 2023-11-22

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms

NCT06141265 2023-11-21

BRAND

Phase 2 Recruiting

Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

NCT05751629 2023-04-21

COHORT-A

Phase 2 Completed

41 enrolled 17 charts

Ovarian Neoplasms

NCT05130515 2023-01-31

CC-ANNIE

Phase 2 Completed

Platinum-resistant Recurrent Clear Cell Ovarian Cancer

NCT05641506 2022-12-07

A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer

Phase 2 Unknown

Nausea, Ovarian Neoplasms

NCT02354586 2022-09-15

QUADRA

Phase 2 Completed

463 enrolled 15 charts 1 FDA

Ovarian Neoplasms

NCT04392102 2022-08-29

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT05311579 2022-04-13

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT04217798 2021-09-01

Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer

Phase 2 Unknown

Ovarian Neoplasms

NCT04885413 2021-08-23

An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients

Phase 2 Unknown

Recurrent/ Advanced Stage Endometrial Cancer Patients

NCT04376073 2020-11-25

ANNIE

Phase 2 Unknown

Platinum-resistant Ovarian Cancer